EU Regulator Backs TRYNGOLZA for Severe High Triglycerides, Decision Due Q4
IONS is trading near its 52-week low of $42.08 (3.5% above the low).
Summary
CHMP adopted a positive opinion recommending EU approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemia, with a final European Commission decision expected in Q4 2026. If confirmed, it would be the first RNA-targeted therapy authorized in the EU for sHTG patients with triglycerides at or above 880 mg/dL. The opinion came ahead of the previously anticipated timeline, and the drug is already approved for sHTG in the U.S. since June. Sobi holds ex-U.S. commercialization rights, so Ionis books royalties rather than direct EU sales. The EU5 market includes roughly 2 million sHTG patients, about 700,000 with triglycerides at or above 880 mg/dL. This adds a second commercial geography for the launch that has been driving Ionis' SG&A higher, and it lands while the stock trades near its 52-week low after the September pelacarsen Phase 3 failure. Watch the EC decision in Q4 2026 for the formal EU authorization.
At the time of this announcement, IONS was trading at $43.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3B. The 52-week trading range was $42.08 to $86.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.